Quarterly report pursuant to Section 13 or 15(d)

4. Commitments and Contingencies (Details Narrative)

v3.20.1
4. Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Technology Rights And Development Agreement [Member] | Houston Pharmaceuticals [Member]    
Contractual obligation $ 50,000 $ 45,833
Patent and Technology License Agreement [Member] | UTMDACC [Member]    
License fee $ 50,000